# Abbott Laboratories vs Danaher: stocks compared

URL: https://funkfolio.com/compare/abt-vs-dhr

> Abbott Laboratories ($181.4B, P/E 40.1) and Danaher ($158.8B, P/E 38.1) compared: size, valuation, margins, debt, cash and price change.

---

## Abbott Laboratories vs Danaher

Abbott Laboratories (ABT), health care, and Danaher (DHR), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Abbott Laboratories is worth $181.4B on the stock market and Danaher $158.8B: Abbott Laboratories is valued at 14% more. Abbott Laboratories trades at 40.1 times earnings and Danaher at 38.1; operating margins in their latest fiscal years were 18.2% and 19.1%. Over the past year Abbott Laboratories's share price has moved -17.3% and Danaher's +1.95%.

### Key facts

- **Abbott Laboratories market value:** $181.4B
- **Danaher market value:** $158.8B
- **Abbott Laboratories P/E:** 40.1
- **Danaher P/E:** 38.1
- **Abbott Laboratories revenue:** $44.3B FY to 2025-12-31
- **Danaher revenue:** $24.6B FY to 2025-12-31
- **Superinvestors holding both:** 2

Market values as of 18 Nov 2026, 04:23 UTC.

Abbott Laboratories vs Danaher: every measure side by side

| Measure | Abbott Laboratories | Danaher |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $181.4B higher | $158.8B lower |
| Revenue | $44.3B higher | $24.6B lower |
| Earnings | $6.5B higher | $3.6B lower |
| Employees | 122,000 higher | 58,000 lower |
| Total assets | $86.7B higher | $83.5B lower |
| Valuation |  |  |
| P/E | 40.1 higher | 38.1 lower |
| P/S | 4.1 lower | 6.5 higher |
| P/B | 3.6 higher | 3.0 lower |
| Dividend yield | 2.35% higher | 0.66% lower |
| Profitability |  |  |
| Operating margin | 18.2% lower | 19.1% higher |
| Balance sheet |  |  |
| Net assets | $52.1B lower | $52.5B higher |
| Total liabilities | $33.9B higher | $30.9B lower |
| Total debt | $12.9B lower | $18.4B higher |
| Cash on hand | $8.5B higher | $4.6B lower |
| Price change |  |  |
| Today | -2.55% lower | -1.80% higher |
| 1 year | -17.3% lower | +1.95% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Abbott Laboratories 80.5, Danaher 102.4.

- Abbott Laboratories (ABT)
- Danaher (DHR)

Abbott Laboratories and Danaher share prices over one year, rebased to 100: Abbott Laboratories ends at 80.5, Danaher at 102.4.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | ABT | DHR |
| --- | --- | --- |
| Nov 28, 2025 | 99.1 | 102.9 |
| Dec 31, 2025 | 96.4 | 103.8 |
| Jan 30, 2026 | 84.1 | 99.3 |
| Feb 27, 2026 | 89.5 | 95.6 |
| Mar 31, 2026 | 79.0 | 86.0 |
| Apr 30, 2026 | 69.8 | 81.2 |
| May 29, 2026 | 65.8 | 82.9 |
| Jun 30, 2026 | 69.8 | 86.4 |
| Jul 31, 2026 | 81.3 | 88.5 |
| Aug 31, 2026 | 84.9 | 96.9 |
| Sep 30, 2026 | 76.0 | 100.5 |
| Oct 30, 2026 | 81.7 | 105.3 |
| Nov 17, 2026 | 80.5 | 102.4 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (2)

- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.5% / 1.6%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.2% / 0.3%

#### Abbott Laboratories only (13)

- [Mason Hawkins](https://funkfolio.com/gurus/mason-hawkins) 4.0%
- [Jensen team](https://funkfolio.com/gurus/jensen-investment) 2.4%
- [Diamond Hill team](https://funkfolio.com/gurus/diamond-hill) 2.2%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 1.9%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) 0.7%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.4%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.4%
- [Paul Tudor Jones](https://funkfolio.com/gurus/paul-tudor-jones) 0.3%
- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.2%
- [Lew Sanders](https://funkfolio.com/gurus/lew-sanders) 0.1%
- [George Soros](https://funkfolio.com/gurus/george-soros) 0.1%
- [Thomas Russo](https://funkfolio.com/gurus/thomas-russo) &lt;0.1%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) &lt;0.1%

#### Danaher only (17)

- [Wallace Weitz](https://funkfolio.com/gurus/wallace-weitz) 7.0%
- [Eric Bannasch](https://funkfolio.com/gurus/eric-bannasch) 4.8%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 4.4%
- [Doug Silverman](https://funkfolio.com/gurus/doug-silverman) 2.3%
- [Dan Loeb](https://funkfolio.com/gurus/dan-loeb) 2.2%
- [Daniel Sundheim](https://funkfolio.com/gurus/daniel-sundheim) 2.1%
- [Steven Romick](https://funkfolio.com/gurus/steven-romick) 1.5%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 1.2%
- [Chase Coleman](https://funkfolio.com/gurus/chase-coleman) 0.4%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.3%
- [Primecap team](https://funkfolio.com/gurus/primecap) 0.3%
- [Louis Bacon](https://funkfolio.com/gurus/louis-bacon) 0.2%
- [Stanley Druckenmiller](https://funkfolio.com/gurus/stanley-druckenmiller) 0.2%
- [Bill Gates](https://funkfolio.com/gurus/gates-foundation) 0.2%
- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.2%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1%
- [Bill Nygren](https://funkfolio.com/gurus/bill-nygren) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Abbott Laboratories / Danaher). [Who owns ABT](https://funkfolio.com/stock/ABT/superinvestors) · [Who owns DHR](https://funkfolio.com/stock/DHR/superinvestors)

### More on Abbott Laboratories

- [Abbott Laboratories (ABT) stock page](https://funkfolio.com/stock/ABT)
- [Abbott Laboratories market cap](https://funkfolio.com/stock/ABT/market-cap)
- [Abbott Laboratories revenue](https://funkfolio.com/stock/ABT/revenue)
- [Abbott Laboratories P/E ratio](https://funkfolio.com/stock/ABT/pe-ratio)
- [Abbott Laboratories operating margin](https://funkfolio.com/stock/ABT/operating-margin)
- [Abbott Laboratories total debt](https://funkfolio.com/stock/ABT/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Danaher

- [Danaher (DHR) stock page](https://funkfolio.com/stock/DHR)
- [Danaher market cap](https://funkfolio.com/stock/DHR/market-cap)
- [Danaher revenue](https://funkfolio.com/stock/DHR/revenue)
- [Danaher P/E ratio](https://funkfolio.com/stock/DHR/pe-ratio)
- [Danaher operating margin](https://funkfolio.com/stock/DHR/operating-margin)
- [Danaher total debt](https://funkfolio.com/stock/DHR/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Abbott Laboratories against its closest peers

- [Abbott Laboratories vs Novo Nordisk](https://funkfolio.com/compare/abt-vs-nvo)
- [Abbott Laboratories vs Gilead Sciences](https://funkfolio.com/compare/abt-vs-gild)
- [Abbott Laboratories vs Pfizer](https://funkfolio.com/compare/abt-vs-pfe)

#### Danaher against its closest peers

- [Danaher vs Pfizer](https://funkfolio.com/compare/dhr-vs-pfe)
- [Danaher vs Intuitive Surgical](https://funkfolio.com/compare/dhr-vs-isrg)
- [Danaher vs Novo Nordisk](https://funkfolio.com/compare/dhr-vs-nvo)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Abbott Laboratories or Danaher?**

By market value, Abbott Laboratories is the larger: $181.4B against $158.8B for Danaher. By revenue in its latest fiscal year, Abbott Laboratories is the larger: $44.3B against $24.6B for Danaher.

**Which has the higher P/E ratio?**

Abbott Laboratories: 40.1, against 38.1 for Danaher. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Danaher: 19.1%, against 18.2% for Abbott Laboratories. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has the higher dividend yield?**

Abbott Laboratories: 2.35%, against 0.66% for Danaher. Dividend yield is the last twelve months' dividends as a share of today's share price.

**Which has more debt?**

Danaher: $18.4B, against $12.9B for Abbott Laboratories. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Abbott Laboratories and Danaher?**

In their latest 13F filings, Brandon Haley and Israel Englander hold both.

### Cite this page

Funkfolio, “Abbott Laboratories vs Danaher”, data as of 18 November 2026. https://funkfolio.com/compare/abt-vs-dhr

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
